A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer

What is this summary about? This summary describes interim (not final) results of a clinical study called TORCHLIGHT. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy in women with triple-negative breast cancer (TNBC) that has come back after being treated ('recurrent TNBC') or has spread to other parts of the body (“metastatic TNBC”). Chemotherapy has been a cornerstone of treatment for recurrent and metastatic TNBC, although it has limited efficacy (ability to produce a desired or intended result). Recent evidence suggests that adding a certain type of immunotherapy (a medicine that boosts the ability of the body’s immune system to kill cancer cells) may improve survival among women with recurrent or metastatic TNBC. Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time women with newly diagnosed recurrent or metastatic TNBC could live without their cancer getting worse (a measurement called 'progression-free survival'). Researchers looked at the safety and efficacy of adding toripalimab among all women with recurrent or metastatic TNBC included in the TORCHLIGHT study, and separately, among a particular subgroup whose breast tumors had a specific protein on their surface called programmed death ligand 1 (PD-L1); these patients are referred to as having 'PD-L1-positive TNBC'. What are the key takeaways? Interim results from the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. The treatment groups with and without toripalimab had similar rates of side effects (an effect of a medicine that is beyond its desired effect and can be harmful), which are tracked to assess safety. What were the main conclusions reported by the researchers? Researchers concluded that results of the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab and chemotherapy lived longer without their TNBC getting worse than women treated with chemotherapy alone, results which support the addition of toripalimab to chemotherapy in women with PD-L1-positive recurrent or metastatic TNBC. Who is this summary for? This summary is intended to provide information to women with recurrent or metastatic TNBC and their family members or caregivers. It may also be helpful for patient advocates and health care professionals.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-12-04
DOI
https://doi.org/10.1080/14796694.2024.2430106
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.28

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer

Jun Qian, Yueyin Pan, Xinhong Wu, Haibo Wang et al.
1 citations
Future Oncology
Cancer Immunotherapy and Biomarkers
0.28
article

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer

Jun Qian, Yueyin Pan, Xinhong Wu, Haibo Wang, Jingfen Wang, Anqin Zhang, Huihua Xiong, Wenbo Yu, Yudong Wu, Xianming Luo, Jiuwei Cui, Shundong Cang, Rong Deng, Xiaohong Wu, Peifen Fu, Jin Yang, Jing Cheng, Tao Sun, Xinlan Liu, Yunwei Han, Patricia Keegan, Yuee Teng, Yongmei Yin, Aimin Zang, Min Yan, Lilin Chen, Xueli Mo, Yongsheng Wang, Qingshan Li, Chuan Wang, Cuizhi Geng, Lili Zhang, Kun Wang, Hui Li, Yuan Sheng, Qingyuan Zhang, Kangsheng Gu, Ying Lin, Yiding Chen, Fanfan Li, Jianyun Nie, Ying Cheng, Xin Zhou, Gang Sun, Yongqiang Zhang, Chaoqiang Yang, Danmei Pang, Xiaojia Wang, Man Li, Tienan Yi, Helong Zhang, Chunwei Xie, Junlan Yang, Quchang Ouyang, Zefei Jiang, Qiang Liu, Shusen Wang, Hongxia Wang
article en
1 citations

Abstract

What is this summary about? This summary describes interim (not final) results of a clinical study called TORCHLIGHT. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy in women with triple-negative breast cancer (TNBC) that has come back after being treated ('recurrent TNBC') or has spread to other parts of the body (“metastatic TNBC”). Chemotherapy has been a cornerstone of treatment for recurrent and metastatic TNBC, although it has limited efficacy (ability to produce a desired or intended result). Recent evidence suggests that adding a certain type of immunotherapy (a medicine that boosts the ability of the body’s immune system to kill cancer cells) may improve survival among women with recurrent or metastatic TNBC. Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time women with newly diagnosed recurrent or metastatic TNBC could live without their cancer getting worse (a measurement called 'progression-free survival'). Researchers looked at the safety and efficacy of adding toripalimab among all women with recurrent or metastatic TNBC included in the TORCHLIGHT study, and separately, among a particular subgroup whose breast tumors had a specific protein on their surface called programmed death ligand 1 (PD-L1); these patients are referred to as having 'PD-L1-positive TNBC'. What are the key takeaways? Interim results from the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. The treatment groups with and without toripalimab had similar rates of side effects (an effect of a medicine that is beyond its desired effect and can be harmful), which are tracked to assess safety. What were the main conclusions reported by the researchers? Researchers concluded that results of the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab and chemotherapy lived longer without their TNBC getting worse than women treated with chemotherapy alone, results which support the addition of toripalimab to chemotherapy in women with PD-L1-positive recurrent or metastatic TNBC. Who is this summary for? This summary is intended to provide information to women with recurrent or metastatic TNBC and their family members or caregivers. It may also be helpful for patient advocates and health care professionals.

Future OncologyVol. 21(4)
Qingdao University (CN), Hebei Medical University (CN), Jiangnan University (CN), Fujian Medical University (CN), Central South University (CN), Anhui University (CN), Xinjiang Medical University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Chongqing University (CN), Second Military Medical University (CN), Dalian Medical University (CN), Chengde Medical University (CN), Jilin University (CN), Anhui Medical University (CN), Kunming Medical University (CN), Chinese PLA General Hospital (CN), Affiliated Hospital of Southwest Medical University (CN), First Affiliated Hospital of Xiamen University (CN), Bioscience (China) (CN), Fudan University Shanghai Cancer Center (CN), Jiangxi Provincial Cancer Hospital (CN), Sun Yat-sen Memorial Hospital (CN), Jilin Province Tumor Hospital (CN), Zhejiang Cancer Hospital (CN), BioReliance (United States) (US), Shandong Tumor Hospital (CN), Second Affiliated Hospital of Dalian Medical University (CN), People's Liberation Army No. 150 Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), First People's Hospital of Foshan (CN), Fourth Hospital of Hebei Medical University (CN), Wuxi Fourth People's Hospital (CN), Hunan Cancer Hospital (CN), Changhai Hospital (CN), Affiliated Hospital of Qingdao University (CN), Sichuan Cancer Hospital (CN), Xiangyang Central Hospital (CN), Beijing Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Jilin University (CN), Ningxia Medical University (CN), Jiangsu Cancer Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Anhui Provincial Hospital (CN), Henan Provincial People's Hospital (CN), Shanghai First People's Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), Peking University Shougang Hospital (CN), Ningxia Medical University General Hospital (CN), First Hospital of China Medical University (CN), Affiliated Hospital of Hebei University (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Second Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN), Jiangsu Province Hospital (CN), Guangdong Provincial People's Hospital (CN), Chongqing Cancer Hospital (CN), Second Affiliated Hospital of Zhejiang University (CN), Tongji Hospital (CN), Chinese People's Liberation Army (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Shandong First Medical University (CN), Union Hospital (CN), First Affiliated Hospital Zhejiang University (CN), China Medical University (CN), Air Force Medical University (CN)
Shanghai Junshi Biosciences
Good health and well-being
Openalex Percentile: Top 34%
Cancer Immunotherapy and Biomarkers
0.28
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.